Skip to content

Shilanski & Associates, Inc.: DTM position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Shilanski & Associates, Inc. on DTM, newest first. How the timeline and the estimate are built.

Shilanski & Associates, Inc. held 28,393 DTM shares at 2025-09-30 per its 13F-HR filed 2025-10-20.

the latest 13F is the newest step

  1. period ended2025-09-30
    13F 28,393 shares
    Change vs previous 13F +1,291 shares

    0.85% of the 13F portfolio, value $3,210,132.

    13F-HR 0002063364-25-000226 filed by Shilanski & Associates, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2025-06-30
    13F 27,102 shares
    Change vs previous 13F +312 shares

    0.85% of the 13F portfolio, value $2,978,759.

    13F-HR 0002063364-25-000164 filed by Shilanski & Associates, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-03-31
    13F 26,790 shares
    Change vs previous 13F +1,207 shares

    0.81% of the 13F portfolio, value $2,584,696.

    13F-HR 0002063364-25-000039 filed by Shilanski & Associates, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2024-12-31
    13F 25,583 shares
    Change vs previous 13F -426 shares

    0.82% of the 13F portfolio, value $2,555,665.

    13F-HR 0001754960-25-000050 filed by Shilanski & Associates, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2024-09-30
    13F 26,009 shares
    Change vs previous 13F not available

    0.67% of the 13F portfolio, value $2,058,005.

    13F-HR 0001754960-24-000556 filed by Shilanski & Associates, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).